NetworkNewsBreaks – Willow Biosciences Inc. (TSX
Post# of 23
(Total Views: 138)
Posted On: 03/03/2021 3:48:01 PM
NetworkNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Updates Status Regarding Acceleration of Expiry Date of Outstanding Warrants
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has released an update on the acceleration of common share warrants that was previously announced. Willow completed the acceleration, which was comprised of 9,320,478 common share purchase warrants issued on Oct. 29, 2020. The completion included the issuance of an estimated 9,259,404 additional common shares, along with cash proceeds for the company of almost $7.9 million. The company now reports a total cash balance of approximately $48.4 million. “We are grateful for the considerable support we have received from our shareholders following our recent warrant accelerations,” said Willow president and CEO Trevor Peters in the press release. “As we enter 2021, we will use the proceeds from the Acceleration alongside the $28.75 million we raised from our recent bought-deal financing to accelerate capital spending towards execution of our commercialization plan for our existing portfolio cannabinoids, and continue to explore opportunities for cannabinoids in development.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has released an update on the acceleration of common share warrants that was previously announced. Willow completed the acceleration, which was comprised of 9,320,478 common share purchase warrants issued on Oct. 29, 2020. The completion included the issuance of an estimated 9,259,404 additional common shares, along with cash proceeds for the company of almost $7.9 million. The company now reports a total cash balance of approximately $48.4 million. “We are grateful for the considerable support we have received from our shareholders following our recent warrant accelerations,” said Willow president and CEO Trevor Peters in the press release. “As we enter 2021, we will use the proceeds from the Acceleration alongside the $28.75 million we raised from our recent bought-deal financing to accelerate capital spending towards execution of our commercialization plan for our existing portfolio cannabinoids, and continue to explore opportunities for cannabinoids in development.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Willow Biosciences Inc. (CANSF) Stock Research Links
Scroll down for more posts ▼